CELLPOINT-DIGITAL
25.4.2022 01:03:06 CEST | Business Wire | Press release
CellPoint Digital , a leading global provider of digital commerce and payment solutions, today announces a partnership with global eCommerce platform for video gamers, MTC Game .
An international retailer, MTC Game provides an online platform for digital codes and services to gamers.
The company will take advantage of CellPoint Digital’s payment orchestration platform. This will enable video gamers, initially in Africa but with plans to expand further, to experience a frictionless checkout, allowing customers to pay via the popular payment methods on the continent including Bank Transfer and Mobile Money options.
By orchestrating payments across Africa, CellPoint Digital is allowing MTC Game to adopt a multi-acquirer payments model that will ultimately open up new opportunities for growth. As a result, CellPoint Digital will help increase MTC Game’s top-line revenue by utilising intelligent routing, increasing authorisations, and providing system uptime transparency, as well as reduce the operational cost of accepting cross border payments.
Sinan BAĞ, Business Development Manager, at MTC Game commented: “ The video game industry is one of the largest media sectors in the world, with gamers in every market. We are excited to expand our payment offering for customers in Africa as we know it will give players in the region more seamless access to the games they want to enjoy.
“CellPoint Digital has been hugely supportive in making this happen. Their close consultative approach on which cross-border payment partners we need to approach, and how to best utilise their platform to meet our market goals, has been indispensable. We look forward to adding more payment methods to our platform and taking on new territories together with the CellPoint Team.”
Kristian Gjerding, CEO of CellPoint Digital added: “In regions like Africa, where video game consoles from all three major markets can be found, it is pivotal for sellers to let their consumers pay with currencies and methods beyond their local options. By partnering with MTC Game, we are helping our new partner with its expansion plans. The video game sector has always felt like a natural extension of our success in the gambling and retail industries, and we are excited to disrupt payments in this dynamic vertical.”
Currently, Africa is MTC Game’s initial market utilising CellPoint Digital’s payment orchestration platform, however as the partnership continues, the potential benefits this change brings will help them expand into other regions as well.
#END#
About CellPoint Digital
CellPoint Digital is a fintech leader in payment orchestration. CellPoint Digital’s main solution is a powerful omni-channel Payment Orchestration Platform that optimises digital payment transactions, from cards or alternative payment methods, and accelerates the deployment of new payment options. Merchants can easily scale their own payment ecosystem across the world, unify the customer payment experience across their website, mobile apps and other channels, optimize the routing of each transaction, increase conversion rates and minimise payment costs.
CellPoint Digital has offices in Copenhagen, Dallas, Dubai, London, Miami, Pune and Singapore. Visit www.cellpointdigital.com to learn more.
About MTC Game
MTC Games or commonly known as MTCGAME is an international online platform which provides digital codes and services to gamers.
Being in the industry over two decades, we are in service of more than 5.000.000 active users worldwide. To offer a better service for our customers, we provide 24/7 online Live Support.
By means of trustworthy service, years of experience in the game industry, and also with variety of local and global payment methods provided, we have grown into one of the most reliable online gaming hub. As MTCGAME, we keep growing by adding new games and partners into our structure.
To discover more visit our portal: www.mtcgame.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005016/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom